Floatz logo

Lonafarnib

Progeria

PRG Science & Technology Co., Ltd.Small moleculePhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Progeria cohort.

Asset / SponsorPhaseRating
PRAVASTATIN
Boston Children's Hospital
Phase 2B
Zoledronate
Boston Children's Hospital
Phase 2B
Progerinin
PRG Science & Technology Co., Ltd.
Phase 2B

Same molecule, other indications

Lonafarnib is also rated in:

metastatic neoplasmDormant
B
Indicative ·
57 / 100
View asset →
renal pelvis/ureter urothelial carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
carcinoma of urethraDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →